Efficacy and Safety of Lobaplatin-TACE in the Treatment of Primary Hepatocellular Carcinoma: A Retrospective Study.

ABSTRACT:

Purpose

To investigate the safety and efficacy of lobaplatin-TACE in treating primary hepatocellular carcinoma.

Methods

The data of 536 patients who underwent TACE in the interventional department from January 2016 to January 2020 were collected. Patients were divided into two groups according to the chemotherapeutic drugs used in TACE.: the epirubicin-TACE group (N = 260) and the lobaplatin-TACE group (N = 276). Primary study endpoint: (1) The tumor response after TACE; (2) The survival rates; Secondary study endpoints:(1) Changes in liver function and blood routine before and after TACE; (2) Occurrence of the post-embolization syndrome and infection after TACE.

Results

The ORR was 35.0% in the epirubicin-TACE group and 51.1% in the lobaplatin-TACE group (p=0.001). T

SUBMITTER: Lu H 

PROVIDER: S-EPMC10186371 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature